Related Experiment Video
Updated: Jun 21, 2026

09:44
Design, Synthesis, and Photochemical Properties of Clickable Caged Compounds
Published on: October 15, 2019
Photoregulation of thrombin aptamer activity using Bhc caging strategy
Yiming Li1, Jing Shi, Zhaofeng Luo
1Department of Chemistry, University of Science and Technology of China, Hefei 230026, China.
Bioorganic & Medicinal Chemistry Letters
|August 18, 2009
Summary
Researchers developed a method to control thrombin aptamer activity using light. By chemically modifying the aptamer with a photolabile group, its biological function can be precisely regulated with spatiotemporal control.
Area of Science:
- Biochemistry
- Molecular Biology
- Photochemistry
Background:
- Aptamers are functional nucleic acid sequences with high specificity for molecular targets.
- Controlling aptamer activity with spatiotemporal precision is crucial for various applications.
- Photolabile protecting groups offer a means to modulate biomolecule function using light.
Purpose of the Study:
- To develop a photoregulated thrombin aptamer system.
- To control aptamer affinity and biological activity using light-induced uncaging.
- To achieve precise spatiotemporal control over aptamer function.
Main Methods:
- Chemical modification of thrombin aptamer with the 6-bromo-7-hydroxycoumarin-4-ylmethyl (Bhc) photolabile group.
- Employing a multiple-caging strategy to achieve reversible inactivation and activation.
- Utilizing photolysis (illumination) to control aptamer activity.
Main Results:
- Successful caging of thrombin aptamer with the Bhc group.
- Demonstration of light-induced inactivation and partial restoration of aptamer activity.
- Achieved spatiotemporal control over aptamer binding affinity.
Conclusions:
- The developed method enables photoregulated control of thrombin aptamer activity.
- This approach offers a convenient tool for precise spatiotemporal manipulation of aptamer function.
- The photoregulated aptamer system has potential applications in molecular diagnostics and therapeutics.

